Literature DB >> 18039109

Molecular pathology of malignant gliomas.

David N Louis1.   

Abstract

Malignant gliomas, the most common type of primary brain tumor, are a spectrum of tumors of varying differentiation and malignancy grades. These tumors may arise from neural stem cells and appear to contain tumor stem cells. Early genetic events differ between astrocytic and oligodendroglial tumors, but all tumors have an initially invasive phenotype, which complicates therapy. Progression-associated genetic alterations are common to different tumor types, targeting growth-promoting and cell cycle control pathways and resulting in focal hypoxia, necrosis, and angiogenesis. Knowledge of malignant glioma genetics has already impacted clinical management of these tumors, and researchers hope that further knowledge of the molecular pathology of malignant gliomas will result in novel therapies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 18039109     DOI: 10.1146/annurev.pathol.1.110304.100043

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   23.472


  294 in total

1.  JLK1486, a Bis 8-Hydroxyquinoline-Substituted Benzylamine, Displays Cytostatic Effects in Experimental Gliomas through MyT1 and STAT1 Activation and, to a Lesser Extent, PPARγ Activation.

Authors:  Céline Bruyère; Sébastien Madonna; Gwendoline Van Goietsenoven; Véronique Mathieu; Jean Dessolin; Jean-Louis Kraus; Florence Lefranc; Robert Kiss
Journal:  Transl Oncol       Date:  2011-06-01       Impact factor: 4.243

2.  A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study.

Authors:  Warren P Mason; Mary Macneil; Petr Kavan; Jacob Easaw; David Macdonald; Brian Thiessen; Shweta Urva; Zarnie Lwin; Lynn McIntosh; Elizabeth Eisenhauer
Journal:  Invest New Drugs       Date:  2011-12-09       Impact factor: 3.850

3.  A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression.

Authors:  Warren P Mason; Karl Belanger; Garth Nicholas; Isabelle Vallières; David Mathieu; Petr Kavan; Annick Desjardins; Antonio Omuro; Didier Reymond
Journal:  J Neurooncol       Date:  2011-11-03       Impact factor: 4.130

4.  Inhibition of Na(+)-K(+)-2Cl(-) cotransporter isoform 1 accelerates temozolomide-mediated apoptosis in glioblastoma cancer cells.

Authors:  Jehad Algharabil; Douglas B Kintner; Qiwei Wang; Gulnaz Begum; Paul A Clark; Sung-Sen Yang; Shih-Hua Lin; Kristopher T Kahle; John S Kuo; Dandan Sun
Journal:  Cell Physiol Biochem       Date:  2012-06-08

Review 5.  [Angiogenesis inhibition in neurooncology. A very promising therapy strategy for malignant glioma].

Authors:  G Tabatabai; R Stupp
Journal:  Nervenarzt       Date:  2010-08       Impact factor: 1.214

6.  Segmentation of Gliomas in Pre-operative and Post-operative Multimodal Magnetic Resonance Imaging Volumes Based on a Hybrid Generative-Discriminative Framework.

Authors:  Ke Zeng; Spyridon Bakas; Aristeidis Sotiras; Hamed Akbari; Martin Rozycki; Saima Rathore; Sarthak Pati; Christos Davatzikos
Journal:  Brainlesion       Date:  2017-04-12

7.  GLISTRboost: Combining Multimodal MRI Segmentation, Registration, and Biophysical Tumor Growth Modeling with Gradient Boosting Machines for Glioma Segmentation.

Authors:  Spyridon Bakas; Ke Zeng; Aristeidis Sotiras; Saima Rathore; Hamed Akbari; Bilwaj Gaonkar; Martin Rozycki; Sarthak Pati; Christos Davatzikos
Journal:  Brainlesion       Date:  2016

8.  Glioma is formed by active Akt1 alone and promoted by active Rac1 in transgenic zebrafish.

Authors:  In Hye Jung; Ga Lam Leem; Dawoon E Jung; Min Hee Kim; Eun Young Kim; Se Hoon Kim; Hae-Chul Park; Seung Woo Park
Journal:  Neuro Oncol       Date:  2013-01-16       Impact factor: 12.300

9.  Attenuated adenosine-to-inosine editing of microRNA-376a* promotes invasiveness of glioblastoma cells.

Authors:  Yukti Choudhury; Felix Chang Tay; Dang Hoang Lam; Edwin Sandanaraj; Carol Tang; Beng-Ti Ang; Shu Wang
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

10.  ELTD1, a potential new biomarker for gliomas.

Authors:  Rheal A Towner; Randy L Jensen; Howard Colman; Brian Vaillant; Nataliya Smith; Rebba Casteel; Debra Saunders; David L Gillespie; Robert Silasi-Mansat; Florea Lupu; Cory B Giles; Jonathan D Wren
Journal:  Neurosurgery       Date:  2013-01       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.